Synopsis: RPG Life Sciences reported mixed quarterly numbers, with strong revenue growth but a sharp decline in reported profit due to base effects from last year’s one-time gain. As exceptional income fades, the company may be entering a phase of cleaner and more...
Synopsis:- Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon & Co. for $14 per share in an all-cash deal worth $11.75 billion in enterprise value, a transaction that vaults India’s largest pharma company into the global...
Synopsis: The shares of this pharmaceutical company surged 11.1 percent following a Rs 216.3 crore block transaction, marking a notable change in ownership with a sizable stake exchanged. The share of this company, which offers services to leading global...
Synopsis: Shares of Sakar Healthcare Ltd surged 13% after the company reported a strong Q3 FY26 performance, with profit more than doubling YoY and QoQ. Robust revenue growth, operating leverage, and improving earnings quality boosted investor confidence despite...
Synopsis: Sun Pharmaceutical Industries is in focus after the company announced a latest capex plan worth Rs 3,000 crore from one of its subsidiaries. The shares of this leading pharma company engaged in the business of manufacturing, developing and marketing a wide...
Synopsis: Laurus Labs is in focus after CITI expects the stock to plunge by another 42 percent, citing its valuations are too stretched and faster capex causing profitability and margins depression in the near term. The shares of this leading research-driven...
Synopsis: Senores Pharmaceuticals jumped sharply after its net profit grew 131% YoY to Rs 30.1 crore due to robust growth in its regulated markets and increased efficiency. Due to strong worldwide demand for its complex generics, revenue increased 56% to Rs 153 crore,...
Synopsis: SMS Pharmaceuticals announced the successful closure of USFDA inspection at its Hyderabad lab. Conducted June 23-25, 2025, the audit ended with zero Form 483 observations; EIR issued with “No Action Indicated” status. During Thursday’s trading session,...
During Thursday’s trading session, the shares of a global pharmaceutical company providing access to affordable and innovative medicines tumbled by nearly 2 percent on BSE, after CITI Research trimmed target price and recommended a “sell” rating on the...
Shares of a leading pharmaceutical company rose nearly 2 percent in today’s trading session after the firm announced it had secured regulatory approval for its new diabetes drug. The development marks a significant milestone in the company’s efforts to expand its...
